Literature DB >> 20546782

Experimental approaches for the treatment of malignant gliomas.

Leopold Arko1, Igor Katsyv, Grace E Park, William Patrick Luan, John K Park.   

Abstract

Malignant gliomas, which include glioblastomas and anaplastic astrocytomas, are the most common primary tumors of the brain. Over the past 30 years, the standard treatment for these tumors has evolved to include maximal safe surgical resection, radiation therapy and temozolomide chemotherapy. While the median survival of patients with glioblastomas has improved from 6 months to 14.6 months, these tumors continue to be lethal for the vast majority of patients. There has, however, been recent substantial progress in our mechanistic understanding of tumor development and growth. The translation of these genetic, epigenetic and biochemical findings into therapies that have been tested in clinical trials is the subject of this review. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546782      PMCID: PMC2939300          DOI: 10.1016/j.pharmthera.2010.04.015

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  404 in total

1.  A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).

Authors:  Roy Rampling; Marc Sanson; Thiery Gorlia; Denis Lacombe; Christina Lai; Myriam Gharib; Walter Taal; Clemens Stoffregen; Rodney Decker; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2012-01-29       Impact factor: 12.300

2.  Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Authors:  John H Sampson; Gary Archer; Christoph Pedain; Eva Wembacher-Schröder; Manfred Westphal; Sandeep Kunwar; Michael A Vogelbaum; April Coan; James E Herndon; Raghu Raghavan; Martin L Brady; David A Reardon; Allan H Friedman; Henry S Friedman; M Inmaculada Rodríguez-Ponce; Susan M Chang; Stephan Mittermeyer; David Croteau; Raj K Puri
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

3.  An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.

Authors:  Efstathia Giannopoulou; Konstantinos Dimitropoulos; Andreas A Argyriou; Angelos K Koutras; Fotinos Dimitrakopoulos; Haralabos P Kalofonos
Journal:  Invest New Drugs       Date:  2009-07-15       Impact factor: 3.850

4.  A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Authors:  David A Reardon; Michael R Zalutsky; Gamal Akabani; R Edward Coleman; Allan H Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; Jennifer A Quinn; Jeremy N Rich; James J Vredenburgh; Annick Desjardins; Sridharan Guruangan; Susan Boulton; Renee H Raynor; Jeanette M Dowell; Terence Z Wong; Xiao-Guang Zhao; Henry S Friedman; Darell D Bigner
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

5.  Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.

Authors:  Stuart A Grossman; Jeffrey Olson; Tracy Batchelor; David Peereboom; Glenn Lesser; Serena Desideri; Xiaobu Ye; Tarek Hammour; Jeffrey G Supko
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

6.  A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

Authors:  Brian Thiessen; Clinton Stewart; Ming Tsao; Suzanne Kamel-Reid; Paula Schaiquevich; Warren Mason; Jacob Easaw; Karl Belanger; Peter Forsyth; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Cancer Chemother Pharmacol       Date:  2010-01       Impact factor: 3.333

7.  Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

Authors:  Shuichi Izumoto; Akihiro Tsuboi; Yoshihiro Oka; Tsuyoshi Suzuki; Tetsuo Hashiba; Naoki Kagawa; Naoya Hashimoto; Motohiko Maruno; Olga A Elisseeva; Toshiaki Shirakata; Manabu Kawakami; Yusuke Oji; Sumiyuki Nishida; Satoshi Ohno; Ichiro Kawase; Jun Hatazawa; Shin-Ichi Nakatsuka; Katsuyuki Aozasa; Satoshi Morita; Junichi Sakamoto; Haruo Sugiyama; Toshiki Yoshimine
Journal:  J Neurosurg       Date:  2008-05       Impact factor: 5.115

8.  Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.

Authors:  Felix Bokstein; Shulim Shpigel; Deborah T Blumenthal
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

Review 9.  TLR3: interferon induction by double-stranded RNA including poly(I:C).

Authors:  Misako Matsumoto; Tsukasa Seya
Journal:  Adv Drug Deliv Rev       Date:  2008-01-02       Impact factor: 15.470

10.  Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.

Authors:  Maria Sandström; Mikael Johansson; Per Bergström; A Tommy Bergenheim; Roger Henriksson
Journal:  J Neurooncol       Date:  2008-01-29       Impact factor: 4.130

View more
  28 in total

1.  Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.

Authors:  Demirkan B Gürsel; Yvette S Connell-Albert; Robert G Tuskan; Theonie Anastassiadis; Jessica C Walrath; Jessica J Hawes; Jessica C Amlin-Van Schaick; Karlyne M Reilly
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Scale to predict survival after surgery for recurrent glioblastoma multiforme.

Authors:  John K Park; Tiffany Hodges; Leopold Arko; Michael Shen; Donna Dello Iacono; Adrian McNabb; Nancy Olsen Bailey; Teri Nguyen Kreisl; Fabio M Iwamoto; Joohee Sul; Sungyoung Auh; Grace E Park; Howard A Fine; Peter McL Black
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

3.  Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.

Authors:  Yohei Mineharu; Neha Kamran; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Cancer Ther       Date:  2014-09-25       Impact factor: 6.261

4.  Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.

Authors:  Xing-Qi Li; Zhi-Gang Ouyang; Sheng-Hua Zhang; Hong Liu; Yue Shang; Yi Li; Yong-Su Zhen
Journal:  J Neurooncol       Date:  2014-05-20       Impact factor: 4.130

5.  A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo.

Authors:  Allan E David; Adam J Cole; Beata Chertok; Yoon Shin Park; Victor C Yang
Journal:  J Control Release       Date:  2011-02-02       Impact factor: 9.776

6.  Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.

Authors:  Francisco das Chagas Abreu da Silveira; Bruno de Almeida Lopes; Clovis Orlando da Fonseca; Thereza Quirico-Santos; Izabel Christina Nunes de Palmer Paixão; Lidia Maria da Fonte de Amorim
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-06       Impact factor: 4.553

Review 7.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

8.  MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.

Authors:  Junchao Cai; JingJing Zhao; Nu Zhang; Xiaonan Xu; Rong Li; Yang Yi; Lishan Fang; Le Zhang; Mengfeng Li; Jueheng Wu; Heng Zhang
Journal:  J Biol Chem       Date:  2015-08-18       Impact factor: 5.157

9.  Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.

Authors:  Xing-Qi Li; Zhi-Gang Ouyang; Sheng-Hua Zhang; Hong Liu; Yue Shang; Yi Li; Yong-Su Zhen
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

10.  YB-1, a new biomarker of glioma progression, is associated with the prognosis of glioma patients.

Authors:  Jin Zheng; Weijiang Dong; Jiangwei Zhang; Guangyue Li; Huilin Gong
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-03-01       Impact factor: 3.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.